Informations générales (source: ClinicalTrials.gov)
18-FDG Tumour Metabolism Changes in PDL1 Superior to 50% Stage III/IV Non Small Cell Lung Cancer During First Line Treatment With Pembrolizumab (iTEP1)
Interventional
N/A
Centre Henri Becquerel (Voir sur ClinicalTrials)
juin 2019
décembre 2023
29 juin 2024
The aim of this study is to describe the early dynamics of 18-FDG uptake in non smal cell
lung cancer during first line treatment with pembrolizumab, and to evaluate whether or
not they differ according to treatment response at 3 months.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Henri Becquerel - 76000 - Rouen - France | Stephanie Becker, MD | Contact (sur clinicalTrials) | |||
| CHU - 76000 - Rouen - France | Luc Thiberville, Md, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Non operable non small cell lung cancer
- Indication of treatment by Pembrolizumab
- PD-L1 status superior to 50 %
- Age more than 18 years
- At least one measurable target
- Written inform consent
- Non operable non small cell lung cancer
- Indication of treatment by Pembrolizumab
- PD-L1 status superior to 50 %
- Age more than 18 years
- At least one measurable target
- Written inform consent
- no treatment by pembrolizumab
- immunosuppressive treatment
- uncontrolled diabete
- Pregnancy or breast-feeding
- curatorship or guardianship
- not possibility to follow-up the procedures of the study due to geographic, social
or psychic reasons